Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market research analyst predicts the cardiac rhythm management devices market in China to grow at an impressive CAGR of around 10% by 2020. Rising incidences of cardiac disorders such as atrioventricular blocks, ventricular fibrillation, cardiac arrest, bradycardia, sick sinus syndrome, and tachycardia are expected to increase the demand for cardiac rhythm management devices in China during the forecast period.
With aging, heart muscles lose their elasticity and ability to respond to different pressure rates which makes older people more susceptible to cardiac disorders. The rising incidences of cardiac disorders, especially in the aging populace, will bolster the market growth for cardiac rhythm management devices until the end of 2020.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Healthcare reform in China
PART 06: Regulatory landscape
PART 07: Insurance coverage and reimbursement in China
PART 08: Opportunities for global and local vendors
PART 09: Market landscape
PART 10: Market segmentation by product
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
PART 17: Appendix
PART 18: Explore Technavio
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.